Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial
- 26 October 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 162 (3), 661-668
- https://doi.org/10.1111/j.1365-2133.2009.09561.x
Abstract
Patients with severe eczema frequently receive systemic glucocorticosteroids. The efficacy of prednisolone and other steroids, however, has never been evaluated appropriately. A meta-analysis indicated that ciclosporin is the best evaluated systemic treatment for eczema. To investigate the comparative efficacy of prednisolone and ciclosporin for severe eczema. In an investigator-initiated double-blind randomized multicentre trial, adults with severe eczema (objective SCORAD > or = 40 and Dermatology Life Quality Index > or = 10) were randomly allocated to receive prednisolone (initial dose 0.5-0.8 mg kg(-1) daily) for 2 weeks followed by placebo for 4 weeks or ciclosporin (2.7-4.0 mg kg(-1) daily) for 6 weeks and followed for another 12 weeks. Concomitant treatment included a moderately potent topical steroid, emollients, and continuation of antihistamines. Primary endpoint was the proportion of patients with stable remission, i.e. > or = 50% SCORAD improvement under active treatment and no flare (> or = 75% of baseline SCORAD) during follow-up. Sample size calculation indicated that 66 patients were needed to see clinically relevant differences between groups. Analysis was by intention-to-treat (ClinicalTrials.gov Identifier: NCT00445081). Because of unexpectedly high numbers of withdrawals due to significant exacerbations of eczema (n = 15/38) an independent data monitoring and safety board proposed early study termination. Thirty-eight patients were randomized and analysed. Stable remission was achieved in one of 21 patients receiving prednisolone compared with six of 17 patients treated with ciclosporin (P = 0.031). Ciclosporin is significantly more efficacious than prednisolone for severe adult eczema. Despite its frequent use in daily practice, prednisolone is not recommended to induce stable remission of eczema.Keywords
This publication has 34 references indexed in Scilit:
- Treatment Following an Evidence-Based Algorithm versus Individualised Symptom-Oriented Treatment for Atopic EczemaDermatology, 2008
- Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based studyBritish Journal of Dermatology, 2007
- What are the best outcome measurements for atopic eczema? A systematic reviewJournal of Allergy and Clinical Immunology, 2007
- Systemic Treatment of Severe Atopic Eczema: A Systematic ReviewActa Dermato-Venereologica, 2007
- Atopic DermatitisNew England Journal of Medicine, 2005
- International Consensus Conference on Atopic Dermatitis II (ICCAD II*): clinical update and current treatment strategiesBritish Journal of Dermatology, 2003
- Atopic dermatitisThe Lancet, 2003
- Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic DermatitisDermatology, 1997
- The cost of atopic eczemaBritish Journal of Dermatology, 1996
- Recombinant interferon gamma therapy for atopic dermatitisJournal of the American Academy of Dermatology, 1993